T. V. Rakitina, A. A. Zeifman, F. N. Novikov, O. V. Stroganov, V. S. Stroylov, I. Svitanko, A. Frank-Kamenetskii, G. G. Chilov, “Novel PARP1 inhibitors potentiate doxorubicin antitumor activity in vitro”, Mendeleev Commun., 25:5 (2015), 364

Эта публикация цитируется в 2 статьях

Communications

Novel PARP1 inhibitors potentiate doxorubicin antitumor activity in vitro

T. V. Rakitina^ab, A. A. Zeifman^c, F. N. Novikov^c, O. V. Stroganov^c, V. S. Stroylov^c, I. Svitanko^cd, A. Frank-Kamenetskii^a, G. G. Chilov^c

^a National Research Centre 'Kurchatov Institute', Moscow, Russian Federation
^b M.M. Shemyakin–Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
^c N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
^d Department of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russian Federation

Аннотация: Six novel potential PARP1 inhibitors were identified by means of substructure search and molecular docking into PAPR1 active site; one compound (STK970217) potentiated the cytotoxicity of doxorubicin in hepatocellular carcinoma HepG2 cells being non-cytotoxic as a single agent, while three other identified compounds inhibited the growth of HepG2 cells both individually and in combination with doxorubicin.

Язык публикации: английский

DOI: 10.1016/j.mencom.2015.09.016